Elaine Chen and Andrew Joseph

BioTech

Novo Nordisk pulls filings for Wegovy in heart failure as it waits for cardiovascular outcomes data

Novo Nordisk is pulling its regulatory submissions to expand the use of its obesity drug Wegovy for a common type of heart failure, saying that

Elaine Chen and Andrew Joseph August 7, 2024

BioTech

Novo’s obesity drug Wegovy lowers cardiovascular risk by 20%, landmark trial finds

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage

Elaine Chen and Andrew Joseph August 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Elaine Chen and Andrew Joseph

Novo Nordisk pulls filings for Wegovy in heart failure as it waits for cardiovascular outcomes data

Novo’s obesity drug Wegovy lowers cardiovascular risk by 20%, landmark trial finds

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe